Impact of a 21-valent pneumococcal conjugate vaccine on pneumococcal disease incidence among adults 65-84 years of age in Belgium: An epidemiological modeling study - PubMed
5 hours ago
- #Belgium-health
- #pneumococcal-vaccine
- #epidemiological-modeling
- The study evaluates the impact of a new 21-valent pneumococcal conjugate vaccine (PCV21) compared to the current PCV20 on pneumococcal disease (PD) incidence in Belgian adults aged 65-84.
- PCV21 is designed to cover more pneumococcal serotypes, potentially reducing invasive PD (IPD) and non-bacteremic pneumococcal pneumonia (NBPP) cases.
- Modeling predicts PCV21 could reduce IPD by 3.68%, inpatient NBPP by 3.08%, and outpatient NBPP by 3.34% by 2036 in adults aged 65-80.
- Over 15 years, PCV21 may prevent 134 fewer IPD cases and 1,195 fewer NBPP cases compared to PCV20 in Belgium.
- Smaller but significant benefits were also projected for the 81-84 age group, supporting PCV21's broader protective impact.